CDTX
USDCidara Therapeutics Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$101.450
Máximo
$105.280
Mínimo
$100.160
Volumen
0.70M
Fundamentos de la Empresa
Capitalización de Mercado
2.5B
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
0.84M
Bolsa
NCM
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today
Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $150 Price Target
HC Wainwright & Co. analyst Sara Nik reiterates Cidara Therapeutics with a Buy and maintains $150 price target.
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive'
JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's game-changing potential.
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
JP Morgan Initiates Coverage On Cidara Therapeutics with Overweight Rating, Announces Price Target of $200
JP Morgan analyst Anupam Rama initiates coverage on Cidara Therapeutics with a Overweight rating and announces Price Target of $200.
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.